Effectiveness of Ultrasound (US) Guided Supraclavicular Block

Not Applicable

Withdrawn

• Conditions: Pain; Analgesia
• Interventions: Drug: 20 ml of ropivacaine 0.5%; Drug: 30 ml of ropivacaine 0.5%; Drug: 40 ml of ropivacaine 0.5%

• Registration Number: NCT00923494
• Lead Sponsor: Baylor College of Medicine

Brief Summary

This research study is being done in order to find out if there is any difference in the effectiveness of ultrasound guided supraclavicular brachial plexus nerve block that can be achieved with 3 different amounts of ropivacaine 0.5% (20 ml, 30 ml, and 40 ml). The investigators want to show if you can have a successful nerve block with less amount of local anesthetic, thus potentially decreasing the risk of side effects.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-05
• Study First Submitted: 2009-06-16
• Study First Submitted QC: 2009-06-17
• Study First Posted: 2009-06-18
• Primary Completion: 2010-12
• Study Completion: 2010-12
• Status Verified: 2017-01
• Last Update Submitted: 2017-01-19
• Last Update Posted: 2017-01-20

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Patients between the ages of 18-64,
• Patients who are ASA I-III, presenting for distal upper extremity surgery. Surgeries to be considered are ORIF of distal upper extremity fractures such as ORIF radius, ORIF ulna, ORIF of any bones in the wrist or hand, and distal upper extremity surgery involving bones or tendons for which postoperative pain is to be expected. No emergency surgeries will be considered.

Exclusion Criteria

• Emergency surgery,
• Patient or surgeon refusal
• Patients for which peripheral nerve block or study medications are contraindicated,
• Patients on chronic analgesic therapy at home,
• History of nerve injury, neuropathy, or known neurologic injury or illness, or inability to properly describe postoperative pain to investigators (language barrier, psychiatric disorder, dementia).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group R20	20 ml of ropivacaine 0.5%	Patient will receive 20 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
Group R30	30 ml of ropivacaine 0.5%	Patient will receive 30 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
Group R40	40 ml of ropivacaine 0.5%	Patient will receive 40 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.

Primary Outcome Measures

Name	Time	Method
Onset of analgesia	First 30 minutes
Duration of analgesia	24 hours

Secondary Outcome Measures

Name	Time	Method
Total analgesic use	First 24 hours

Trial Locations

Locations (1)

Ben Taub General Hospital; 🇺🇸 Houston, Texas, United States